Differential counts of leukocytes in mouse BALF.

AimsAsthma is characterized by chronic airway inflammation, persistent cough, wheezing, and dyspnea. This study aimed to evaluate the efficacy of Limosilactobacillus reuteri VHProbi® M07 (M07) administration in alleviate the asthma severity in a mice model.Methods and resultsIn vitro studies confirmed that M07 can survive and proliferate within the gastrointestinal tract. BALB/c mice were administered M07 both before and after ovalbumin (OVA) challenge. Serum levels of OVA-specific immunoglobulin (Ig) E and IgG1, inflammatory cells and cytokines in bronchoalveolar lavage fluid were assessed, along with histopathological examination of lung tissue. Compared to the placebo (PLA) group, mice treated with M07 exhibited significantly lower levels of OVA-specific IgE and IgG1 (P P P P ConclusionsOral administration of M07 mitigated key features of inflammatory responses in the OVA-induced mice asthma model. These findings suggest that M07 holds therapeutic potential for the treatment of allergic asthma.

研究背景与目的：哮喘（Asthma）以慢性气道炎症、持续性咳嗽、喘息及呼吸困难为核心特征。本研究旨在评估罗伊氏乳杆菌（Limosilactobacillus reuteri）VHProbi® M07（下称M07）干预对小鼠哮喘模型病情严重程度的改善效果。
方法与结果：体外实验证实，M07可在胃肠道内存活并增殖。将BALB/c小鼠在卵清蛋白（ovalbumin, OVA）致敏前后给予M07干预。检测血清中OVA特异性免疫球蛋白（immunoglobulin, Ig）E、IgG1水平，支气管肺泡灌洗液（bronchoalveolar lavage fluid）中的炎症细胞与细胞因子水平，并对肺组织进行病理组织学检查。与安慰剂（PLA）组相比，M07干预组小鼠的OVA特异性IgE与IgG1水平显著降低（P P P P）。
结论：口服M07可缓解卵清蛋白诱导的小鼠哮喘模型中炎症应答的关键特征。上述研究结果表明，M07具备治疗过敏性哮喘的潜在应用价值。